



#23 / \$1635

BOX DD  
Attorney Docket No. 25158

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

WRIGHT et al.

Serial No. 08/886,313

Examiner: M. Schmidt

Filed: June 30, 1997

Group Art Unit: 1635

For: **INHIBITING NEOPLASTIC CELLS UTILIZING THE RIBONUCLEOTIDE  
REDUCTASE UTR**

RECEIVED

JAN 27 2003

TECH CENTER 1600/2900

TRANSMITTAL LETTER

The Commissioner for Patents  
Washington, D.C. 20231


Sir:

Submitted herewith for filing in the U.S. Patent and Trademark  
Office is the following:

- (1) Transmittal Letter;
- (2) Information Disclosure Statement;
- (3) Form PTO-1449 citing ten (10) references;
- (4) Copies of ten (10) references cited; and
- (5) Check No. 18013 in the amount of \$180.00.

Respectfully submitted,  
**NATH & ASSOCIATES PLLC**

By:

  
Gary M. Nath  
Registration No. 26,965  
Todd L. Juneau  
Registration No. 40,669  
Customer No. 20529

Date: January 21, 2003

**NATH & ASSOCIATES PLLC**

1030 15<sup>th</sup> Street, NW - 6<sup>th</sup> Floor  
Washington, D.C. 20005

GMN/SMM\IDS.TL



#23/K.T.  
3/7  
F.D.S.  
BOX DD

Attorney Docket No. 25158

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

WRIGHT et al.

Serial No. 08/886,313

Examiner: M. Schmidt

Filed: June 30, 1997

Group Art Unit: 1635

For: **INHIBITING NEOPLASTIC CELLS UTILIZING THE RIBONUCLEOTIDE  
REDUCTASE UTR**

RECEIVED  
JAN 27 2003  
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Pursuant to Applicant's duty of disclosure under 37 C.F.R. §§1.56 and 1.97-1.99, the documents listed on the attached Form PTO-1449 are being brought to the attention of the Examiner in charge of the above-identified application. The fee as prescribed by 37 CFR 1.17(p) is enclosed herewith.


Copies of the documents are attached herewith with a completed Form PTO-1449. The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record

in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,  
**NATH & ASSOCIATES PLLC**

By:



Gary M. Nath  
Registration No. 26,965  
Todd L. Juneau  
Registration No. 40,669  
Customer No. 20529

Date: January 21, 2003  
**NATH & ASSOCIATES PLLC**  
1030 15<sup>th</sup> Street, NW - 6<sup>th</sup> Floor  
Washington, D.C. 20005  
GMN/SMM\IDS.



#23/I.D.S.

Page 1 of 3

FORM PTO-1449 <b>INFORMATION DISCLOSURE CITATION</b>	Atty Docket 25158	Serial No. 08/886,313
	Applicant Wright et al.	
	Filing Date 6/30/97	Group Art Unit 1635

## U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Issue Date	Name	Class	Sub-Class	Filing Date
	AA	5,474,981	12/12/95	Leder et al.	514	12	3/23/94
	AB	5,601,818	2/11/97	Freeman et al.	424	93.21	12/8/94
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

RECEIVED

JAN 27 2003

TECH CENTER 1600/2900


		Document Number	Pub. Date	Name	Class	Sub-Class	Filing Date
	AL	WO 98/00532	1/8/98	Wright et al.			30.6.97
	AM						
	AN						
	AO						
	AP						

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	Braidotti et al. 1993 J. Biol. Chem. 268(2):1109-1117
	AS	Fan et al. 1996 Cancer Research 56(19): 4366-4369.
	AT	Gomez-Navarro et al. 1999. European Journal of Cancer 35(6):867-885.

Examiner	Date Considered
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609.  
Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to Applicant.



FORM PTO-1449

## INFORMATION DISCLOSURE CITATION

Atty Docket  
25158Serial No.  
08/886,313

Applicant

Wright et al.

Filing Date  
6/30/97Group Art Unit  
1635

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Issue Date	Name	Class	Sub-Class	Filing Date

RECEIVED

JAN 27 2003

TECH CENTER 1600/2900

Document Number	Pub. Date	Name	Class	Sub-Class	Filing Date

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

BA	Kijima et al. Pharm. Therapeutics 68(2):247-267
BB	McCluskie et al. Molecular Medicine 5:287-300
BC	Schabet and Herrlinger 1998. Journal of Neuro-oncology 38:199-205


Examiner

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609.

Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE CITATIONAtty Docket  
25158Serial No.  
08/886,313Applicant  
Wright et al.Filing Date  
6/30/97Group Art Unit  
1635

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Issue Date	Name	Class	Sub- Class	Filing Date

**RECEIVED****JAN 27 2003****TECH CENTER 1600/2800**

Document Number	Pub. Date	Name	Class	Sub- Class	Filing Date

**OTHER** (Including Author, Title, Date, Pertinent Pages, etc.)

CA		Tsa et al. 1991. J. Biol. Chem. 266(34): 23053-23059.

Examiner

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609.  
 Draw line through citation if not in conformance and not considered.  
 Include copy of this form with next communication to Applicant.